Epilepsia · 1997 · 15 citations · 6 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyEpilepsyEpileptologyAntiepileptic PharmacologyAntiepileptic PharmacotherapyDose SelectionAntiepileptic Drug DosingAntiepileptic Drug SafetyDose SafetyMaximum Observed ConcentrationMonotherapy Of EpilepsyPharmacokinetic Parameter AnalysisPharmacokinetic ParametersTreatment Outcomes In Epilepsy
PURPOSE: Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs. METHODS: In study A, newly diagnosed subjects with epilepsy receiving FBM monotherapy at a starting dose of 1,200 mg/day (400 mg/three times daily, t.i.d.) and increased 1,200 mg/day, if tolerated, at 14-day intervals to 3,600 mg/day were investigated. In study B, epilepsy subjects with prior FBM monotherapy exposure received ascending FBM doses in five consecutive 14-day periods with a starting dose of 3,600 mg/day (1,200 mg t.i.d.) FBM. In each successive period, if FBM was well tolerated, the dose was increased by 600 mg/day to a maximum of 6,000 mg/day (2,000 mg t.i.d.). RESULTS: The pharmacokinetic parameter estimates maximum observed concentration (Cmax), area under the concentration-time curve (AUCtau) Ctrough, and Cav showed a linear dependence to dose above the 1,200-6,000 mg/day FBM dose range (F-tests; p < 0.0001) with apparent clearance (Cl/kg) and Tmax (time to Cmax) independent of dose. When AUCtau, Cmax and Ctrough were adjusted for dose, there were no significant differences between the dosing periods. CONCLUSIONS: The data establish that plasma concentrations of FBM are linear with respect to dose to 6,000 mg/day. In addition, FBM was safely administered at these doses for periods as long as 14 days to epileptic subjects with prior exposure to FBM. FBM-naive subjects appeared to report more adverse experiences (generally of mild to moderate severity) than did subjects with prior FBM exposure.
6
D. Schmidt · Epilepsy Research · 1987 · 324 citations
Felbamate pharmacokinetics in the rat, rabbit, and dog.
V E Adusumalli, J Yang, Keith Wong et al. · Drug Metabolism and Disposition · 1991 · 48 citations
Nina M. Graves, Thomas M. Ludden, Gregory B. Holmes et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 1989 · 29 citations